Table 2.

Effectiveness of the primary treatment of EL-4 lymphomas in C57BL/6 mice and proportion of tumour-resistant long-term survivors

Treatment with Dox–PHPMA–HuIg	Pa	Tb	Tb	Tb	Tb	Tb
Dose (Dox eq. mg/kg)	5 ×, total 20	5 ×, total 20	1 ×, total 10	1 ×, total 15	2 ×, total 15	1 ×, total 20
Route of administration	i.p.	i.p.	i.v.	i.v.	i.v.	i.v.
Complete regression of primary tumour (%)	80	55.2	62.5	81	88.9	100
Mice resistant to a second tumour (%)c	0	100	ND	66.7	ND	50

Summary data from all experiments are listed

P protective treatment scheme, T therapeutic scheme, ND not determined

^aThe therapy started on day 1 after tumour transplantation and was given as five equal doses injected every other day

^bThe first or the single dose was given when tumours were well established, usually on day 9–10 post-transplantation

^cThe resistance in long-term survivors was verified by the injection of 1 × 10⁵ EL-4 tumour cells s.c. After the tumour transplantation, the mice were left without treatment